Drug reference

azd7442

combination of two long-acting human mAbs · SARS-CoV-2 monoclonal antibody

combination of two long-acting human mAbsSARS-CoV-2 monoclonal antibody

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

AZD7442 is a combination of two long-acting human monoclonal antibodies, modified in an Fc format for extended half-life, authorized for the prevention of COVID-19 in high-risk individuals.

Indications

prevention of disease in high-risk individuals (COVID-19)for any individual 12 years or older (marketing authorization)

Related guidelines

Cardiovascular disease prevention

ESC · Cardiology · 2021

Primary prevention of cardiovascular disease

AHA · Cardiology · 2019

Diabetic foot — clinical management

MOHFW · Endocrinology · 2021

Coeliac disease

OTHER · Gastroenterology · 2016

Inflammatory bowel disease

OTHER · Gastroenterology · 2015

Ask House about azd7442

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team